Download the 2026 Economic Impact Report
Join Now
Join Now

NeuroSkye Therapeutics: Diagnostics Startup Selected for Drive Accelerator Program

SOUTH CAROLINA – April 28, 2026 – NeuroSkye Therapeutics is a translational biotechnology company developing human BBB and blood-tumor-barrier (BTB) functional diagnostic platforms to inform treatment decisions in brain tumors. Operating at the intersection of neuro-oncology, precision diagnostics, and translational medicine, NeuroSkye addresses a critical gap in therapy selection by evaluating drug delivery feasibility across the BBB/BTB, enabling more informed, delivery-based clinical decision support and recurrence planning.

Visit Neuroskyetherapeutics.com
Follow on LinkedIn

Solutions

NeuroSkye has developed a human, patient-derived BBB and BTB functional diagnostic platform designed to inform treatment decisions in brain tumors. The platform uses standardized human assembloid models to evaluate whether clinically relevant therapies can penetrate and persist across the BBB/BTB, providing delivery feasibility insight that complements existing molecular and imaging diagnostics.

By focusing on drug delivery as a prerequisite for efficacy, NeuroSkye aims to reduce treatment uncertainty and support more informed therapy selection and recurrence planning. The company is advancing the platform toward a CLIA-facing laboratory-developed test, with the long-term goal of integrating delivery-informed decision support into neuro-oncology workflows and clinical trial stratification.

Strengths

  • Human-Relevant Modeling: NeuroSkye’s platform leverages patient-derived BBB and BTB assembloids built on over a decade of peer-reviewed academic research, providing a biologically relevant system to evaluate drug delivery in human brain tumor contexts rather than relying on animal or barrier-free models.
  • Delivery-Focused Differentiation: Unlike genomics and imaging, which characterize tumor biology, NeuroSkye functionally evaluates drug penetration and retention across the BBB/BTB. This provides a complementary, delivery-focused layer of insight – addressing whether therapies can reach the tumor as a prerequisite for efficacy.
  • Translational Design: The platform is engineered with standardized workflows, quality-control metrics, and reproducibility benchmarks to support progression toward a CLIA-facing laboratory-developed test rather than remaining a research-only model.
  • Clinical Alignment: NeuroSkye is actively engaging clinicians and patient stakeholders to ensure its decision-support outputs integrate with tumor board workflows and address real-world treatment and recurrence planning needs.

Meet the Founder

Choi-Fong Cho, Ph.D. | Founder

Meet the Spring 2026 Drive Cohorts

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Join Today!

Paige Durham

SCbio is pleased to welcome Paige Durham to the team as communications coordinator to creatively and effectively communicate the value of the life science association’s programs and initiatives.

Durham will be responsible for developing and distributing high-quality content across multiple communications channels to build, advance and grow South Carolina’s life sciences industry, a key business sector for economic prosperity for the Palmetto State.

“SCbio is excited to welcome Paige to our team as our new communications coordinator. Paige brings fresh ideas and a strong background in communications that will be invaluable as we continue to strengthen our engagement with our audience,” said SCbio President and CEO James Chappell. “We are confident that her skills and experience will be crucial in advancing our communication strategies and supporting our mission.”

Before joining SCbio, Durham was the Membership and Communications Manager at the South Carolina Pharmacy Association (SCPhA), where she used her photography, design and writing skills to create content tailored to pharmacy professionals. Durham’s effective communication skills guaranteed the delivery of brand-specific material that captured the eye of her audience.

During her time at SCPhA, Durham created and edited the Palmetto Pharmacist Journal, using her creative vision to showcase members, educational institutions and industry news. Her communications efforts successfully gained new followers for the organization over the course of a year, increasing brand visibility and promoting the pharmacy profession.

Durham holds a Bachelor of Science in hospitality and tourism management and a Bachelor of Science in business administration from the College of Charleston.

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.